Business Overview: MapLight Therapeutics, Inc. (NASDAQ: MPLT)

---

Executive Summary

MapLight Therapeutics, Inc. is a California-based clinical-stage biopharmaceutical company developing treatments for brain diseases, including schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder. Its lead candidate, ML-007C-MA, is in Phase 2 trials for schizophrenia (initiated July 2025) and Alzheimer's disease psychosis (initiated September 2025), with both studies targeting 2027 readouts. The company is backed by major pharmaceutical and life-sciences investors including Sanofi and Novo Holdings (the parent company of Novo Nordisk), and raised a $372.5 million Series D round shortly before its IPO.

As a clinical-stage biotech, MapLight has no product revenue and, like virtually all companies at this stage, depends entirely on external financing to fund drug development. As of mid-2025 it reported an accumulated deficit of $251.6 million and $60.5 million in cash, with its own filings acknowledging it will require substantial additional financing beyond IPO proceeds — a normal and expected characteristic of pre-commercial clinical-stage biopharmaceutical companies rather than a sign of operational distress.

---

1. Core Business Model & How They Work

[ Preclinical Target Discovery (CNS Receptors) ] ➡️ [ IND-Enabling Studies ] ➡️ [ Phase 1/2 Clinical Trials ] ➡️ [ Regulatory Readout / FDA Interaction ] ➡️ [ Partnership, Licensing, or Commercialization ]

MapLight's model is standard for clinical-stage CNS biopharma: fund multi-year clinical trials through equity financing and strategic investment, aiming to generate human proof-of-concept data strong enough to support either a later-stage pivotal program, a pharma partnership, or eventual commercialization, rather than near-term product sales.

---

2. Business Segments

MapLight operates as a single clinical-stage biopharmaceutical business; it does not report discrete commercial segments, as it has no marketed products.

┌───────────────────────────────────┐
│     MapLight Therapeutics, Inc.      │
└──────────────────┬─────────────────────┘
                    │
      ┌─────────────┼──────────────┬───────────────┐
      ▼             ▼              ▼                ▼
ML-007C-MA     ML-004          Preclinical:     Preclinical:
(Schizophrenia  (Autism         Parkinson's      Hyperactivity/
+ Alzheimer's   spectrum        disease          Impulsivity/
psychosis,      disorder,       candidate        Agitation
Phase 2)        Phase 2)        (IND-enabling     candidate
                                 planned 2026)    (IND-enabling
                                                   planned 2026)

---

3. Product Portfolio (Pipeline)

---

4. Competitive Landscape

• Schizophrenia: Bristol Myers Squibb's Cobenfy (a recently approved novel-mechanism antipsychotic) is the most direct named competitor/comparator, alongside LB Pharmaceuticals' pipeline candidate.
• CNS biotech peers more broadly: MapLight competes for capital, clinical trial sites, and eventual market share against a wide field of well-funded CNS-focused biopharmaceutical companies.
• Big pharma as both competitor and potential partner: Sanofi and Novo Holdings are investors, illustrating how large pharmaceutical companies in CNS therapeutics can be simultaneously competitors and strategic backers/acquirers.

              Clinical Stage (Later / De-risked)
                           │
   BMS (Cobenfy, approved) ●
                           │
   ─────────────────────────────────────────────
                           │        ● MapLight (Phase 2)
   LB Pharmaceuticals ●    │
                           │
              Clinical Stage (Earlier / Higher Risk)

---

5. Strategic Strengths & Risks

Strengths

• High-profile strategic backing from Sanofi and Novo Holdings signals validation from sophisticated pharmaceutical investors with deep CNS drug development expertise.
• Multiple shots on goal — two indications for the lead asset (schizophrenia and Alzheimer's psychosis) plus a second clinical program (autism) and two preclinical candidates reduce single-asset binary risk somewhat.
• Large recent capital raise ($372.5 million Series D, plus IPO proceeds) provides multi-year runway for the current clinical program slate.

Risks

• No revenue and a going-concern-adjacent funding profile — the company explicitly states it will require substantial additional financing beyond IPO proceeds, a standard but real risk for clinical-stage biotech.
• Binary clinical trial risk — Phase 2 readouts (targeted 2027 for the lead programs) could fail to show efficacy or an acceptable safety profile, which would be highly value-destructive.
• Competitive and regulatory risk in CNS drug development, a therapeutic area with a long history of clinical trial failures industry-wide.
• Long timeline to any potential revenue — even successful Phase 2 readouts in 2027 would require subsequent Phase 3 trials and FDA review before commercialization.

---

6. Financial Overview

---

7. Summary Conclusion

MapLight Therapeutics represents a classic clinical-stage CNS biotech risk/reward profile: substantial big-pharma-backed capital and a multi-shot pipeline targeting large, underserved psychiatric and neurological disease areas, set against the binary risk inherent in Phase 2 clinical trials and a funding model that depends on continued access to capital markets rather than product revenue. The 2027 readouts for its lead asset in schizophrenia and Alzheimer's psychosis will be the defining near-term catalysts for the business.